KR101530353B1 - 사이토킨 유도체 - Google Patents

사이토킨 유도체 Download PDF

Info

Publication number
KR101530353B1
KR101530353B1 KR1020097003947A KR20097003947A KR101530353B1 KR 101530353 B1 KR101530353 B1 KR 101530353B1 KR 1020097003947 A KR1020097003947 A KR 1020097003947A KR 20097003947 A KR20097003947 A KR 20097003947A KR 101530353 B1 KR101530353 B1 KR 101530353B1
Authority
KR
South Korea
Prior art keywords
delete delete
amino acid
polypeptide
acid sequence
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020097003947A
Other languages
English (en)
Korean (ko)
Other versions
KR20090060281A (ko
Inventor
올리비어 하트레이
Original Assignee
민타카 파운데이션 포 메디컬 리써치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 민타카 파운데이션 포 메디컬 리써치 filed Critical 민타카 파운데이션 포 메디컬 리써치
Publication of KR20090060281A publication Critical patent/KR20090060281A/ko
Application granted granted Critical
Publication of KR101530353B1 publication Critical patent/KR101530353B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
KR1020097003947A 2006-07-25 2007-07-25 사이토킨 유도체 Active KR101530353B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0614755.7 2006-07-25
GBGB0614755.7A GB0614755D0 (en) 2006-07-25 2006-07-25 Cytokine derivatives
PCT/IB2007/003026 WO2008012689A2 (en) 2006-07-25 2007-07-25 Cytokine derivatives

Publications (2)

Publication Number Publication Date
KR20090060281A KR20090060281A (ko) 2009-06-11
KR101530353B1 true KR101530353B1 (ko) 2015-06-26

Family

ID=37006114

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097003947A Active KR101530353B1 (ko) 2006-07-25 2007-07-25 사이토킨 유도체

Country Status (25)

Country Link
US (2) US8686111B2 (enExample)
EP (1) EP2076532B1 (enExample)
JP (1) JP5224603B2 (enExample)
KR (1) KR101530353B1 (enExample)
CN (1) CN101511867B (enExample)
AT (1) ATE490270T1 (enExample)
AU (1) AU2007278894B2 (enExample)
BR (1) BRPI0715331B8 (enExample)
CA (1) CA2658806C (enExample)
CY (1) CY1111630T1 (enExample)
DE (1) DE602007010969D1 (enExample)
DK (1) DK2076532T3 (enExample)
ES (1) ES2361455T3 (enExample)
GB (1) GB0614755D0 (enExample)
HR (1) HRP20110146T1 (enExample)
ME (1) ME01320B (enExample)
MX (1) MX2009000918A (enExample)
NZ (1) NZ575092A (enExample)
PL (1) PL2076532T3 (enExample)
PT (1) PT2076532E (enExample)
RS (1) RS51854B (enExample)
RU (1) RU2461567C2 (enExample)
SI (1) SI2076532T1 (enExample)
WO (1) WO2008012689A2 (enExample)
ZA (1) ZA200901342B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600091033A1 (it) * 2016-09-08 2018-03-08 Bioimmunizer Sagl Ceppi di batteri probiotici appartenenti al genere Bifidobacterium e loro estratti di cellule probiotiche (ECP) aventi proprietà immunostimolanti.
MX2020012782A (es) * 2018-05-28 2021-04-28 ORION Biotechnology Switzerland Sarl Inhibidor de ccr5 para el uso en el tratamiento de cancer.
CN112469430B (zh) * 2018-05-28 2024-12-24 日内瓦大学 抑制大脑炎症的方法
EP4646232A1 (en) 2023-01-06 2025-11-12 Université de Genève Variant ligand conjugates for payload delivery
WO2025172252A1 (en) 2024-02-15 2025-08-21 Novo Nordisk A/S Protracted ccr5 antagonists and uses thereof
WO2025176787A1 (en) 2024-02-22 2025-08-28 Orion Biotechnology Holding Sa Ccl5 variants for modulating gpr75
WO2025186255A1 (en) 2024-03-06 2025-09-12 Orion Biotechnology Holding Sa Gipr inhibitors and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044462A1 (fr) * 1996-05-22 1997-11-27 Institut Pasteur Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
WO2003022884A2 (en) * 2001-09-05 2003-03-20 Universite Pierre Et Marie Curie (Paris Vi) Methods for construction and screening of libraries of chemokine variants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0702693A1 (en) * 1993-06-09 1996-03-27 Connaught Laboratories Limited Tandem synthetic hiv-1 peptides
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2005112567A2 (en) 2004-05-03 2005-12-01 University Of Maryland Biotechnology Institute Vaginal microbicide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044462A1 (fr) * 1996-05-22 1997-11-27 Institut Pasteur Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
WO2003022884A2 (en) * 2001-09-05 2003-03-20 Universite Pierre Et Marie Curie (Paris Vi) Methods for construction and screening of libraries of chemokine variants

Also Published As

Publication number Publication date
WO2008012689A2 (en) 2008-01-31
US9328153B2 (en) 2016-05-03
MX2009000918A (es) 2009-08-26
DE602007010969D1 (de) 2011-01-13
RS51854B (sr) 2012-02-29
PT2076532E (pt) 2011-03-02
EP2076532A2 (en) 2009-07-08
RU2009106436A (ru) 2010-08-27
CN101511867B (zh) 2014-04-09
DK2076532T3 (da) 2011-03-07
GB0614755D0 (en) 2006-09-06
US20130330305A1 (en) 2013-12-12
HK1131162A1 (en) 2010-01-15
JP5224603B2 (ja) 2013-07-03
US20090317363A1 (en) 2009-12-24
KR20090060281A (ko) 2009-06-11
BRPI0715331B1 (pt) 2021-04-13
AU2007278894A1 (en) 2008-01-31
BRPI0715331B8 (pt) 2021-05-25
CN101511867A (zh) 2009-08-19
BRPI0715331A2 (pt) 2013-07-16
CA2658806C (en) 2017-01-03
CA2658806A1 (en) 2008-01-31
CY1111630T1 (el) 2015-10-07
EP2076532B1 (en) 2010-12-01
ATE490270T1 (de) 2010-12-15
RU2461567C2 (ru) 2012-09-20
JP2009544304A (ja) 2009-12-17
WO2008012689A3 (en) 2008-05-08
SI2076532T1 (sl) 2011-06-30
ME01320B (me) 2013-12-20
AU2007278894B2 (en) 2012-08-09
NZ575092A (en) 2011-08-26
PL2076532T3 (pl) 2011-07-29
US8686111B2 (en) 2014-04-01
HRP20110146T1 (hr) 2011-06-30
ES2361455T3 (es) 2011-06-17
ZA200901342B (en) 2010-11-24

Similar Documents

Publication Publication Date Title
KR101530353B1 (ko) 사이토킨 유도체
ES2462740T3 (es) Interacciones proteína-proteína en virus de inmunodeficiencia humana
US9155795B2 (en) CXCR4 receptor compounds
EP1161455B1 (en) A novel chimeric protein for prevention and treatment of hiv infection
RU2290197C2 (ru) Фармацевтическое средство для лечения вич-инфекции, содержащая его композиция и способы его применения
KR20210023737A (ko) 신규 인터페론 람다 변이체 및 이의 제조방법
WO2001010893A2 (en) Il-16 antagonists
ES2391237T3 (es) Composiciones y métodos para tratar disfunción eréctil
CN108295242A (zh) 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用
KR101138930B1 (ko) Ｈⅰｖ ｎｃ 단백질을 포함하는 ａⅰｄｓ 예방 및 치료용조성물
HK1131162B (en) Cytokine derivatives
CN101235083B (zh) 抗hiv-i的多肽、其编码序列及其用途
CN120399096A (zh) 靶向CCR5和gp41的双功能融合蛋白及其在制备抗人类免疫缺陷病毒的药物中的应用
WO2022066798A1 (en) Interferon tau fc-fusion proteins and methods for treating coronavirus infections
CN101838318A (zh) 抗hiv-i的多肽、其编码序列及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090225

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120628

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131125

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140520

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131125

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PJ0201 Trial against decision of rejection

Patent event date: 20140617

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140520

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20150406

Appeal identifier: 2014101003657

Request date: 20140617

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20140617

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20140617

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20140123

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140813

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20150406

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20140721

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150615

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150616

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180516

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180516

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190515

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190515

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20200515

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210430

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20220614

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240604

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20250523

Start annual number: 11

End annual number: 11